Review
Varicella zoster virus redux
Affiliations
- PMID: 19306605
Item in Clipboard
Review
Varicella zoster virus redux
Herpes.
2009 Jan.
Abstract
In May 2008, the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention in the USA recommended the routine administration of a live-attenuated high-potency varicella zoster vaccine to all adults over 60 years of age without specific contraindications, for the prevention and attenuation of herpes zoster (HZ). Nevertheless, many physicians still consider this vaccine to be of marginal value. This is not a reasonable conclusion. This short article reviews available data.
Similar articles
-
Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.Vaccine. 2009 Feb 5;27(6):882-7. doi: 10.1016/j.vaccine.2008.11.077. Epub 2008 Dec 9. Vaccine. 2009. PMID: 19071175
-
Perspective on live varicella vaccine.J Infect Dis. 2008 Mar 1;197 Suppl 2:S242-5. doi: 10.1086/522151. J Infect Dis. 2008. PMID: 18419404
-
Zoster vaccine live.Pharmacotherapy. 2007 Jul;27(7):1013-9. doi: 10.1592/phco.27.7.1013. Pharmacotherapy. 2007. PMID: 17594207 Review.
-
Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008.Am J Prev Med. 2011 Feb;40(2):e1-6. doi: 10.1016/j.amepre.2010.10.012. Am J Prev Med. 2011. PMID: 21238856
-
Zoster vaccine: current status and future prospects.Clin Infect Dis. 2010 Jul 15;51(2):197-213. doi: 10.1086/653605. Clin Infect Dis. 2010. PMID: 20550454 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical